Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2026)

Indivior Pharmaceuticals' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $26.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 33.33% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was $26.0 million, a 33.33% decrease from a year earlier, with the FY2025 full-year figure at $27.0 million, down 30.77% from the prior year.
• Other Non-Current Assets slipped to $26.0 million in Q1 2026 per INDV's latest filing, from $27.0 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $44.0 million in Q2 2025 and bottomed at $26.0 million in Q1 2026.
• The 5-year median for Other Non-Current Assets is $37.0 million (2022), against an average of $34.5 million.
• Across the five-year window, Other Non-Current Assets plunged 64.15% in 2022 and rose 8.33% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $38.0 million in 2022, then slipped by 5.26% to $36.0 million in 2023, then grew by 8.33% to $39.0 million in 2024, then slumped by 30.77% to $27.0 million in 2025, then fell by 3.7% to $26.0 million in 2026.
• Per Business Quant, the three latest INDV Other Non-Current Assets figures stand at $26.0 million (Q1 2026), $27.0 million (Q4 2025), and $27.0 million (Q3 2025).